Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study

INTRODUCTION: Upadacitinib is a Janus kinase inhibitor under investigation in patients with psoriatic arthritis (PsA). This study assessed the 56-week efficacy and safety of upadacitinib in patients with PsA and an inadequate response or intolerance to biologic therapy. METHODS: In the phase 3 SELEC...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip J., Lertratanakul, Apinya, Papp, Kim A., van den Bosch, Filip E., Tsuji, Shigeyoshi, Dokoupilova, Eva, Keiserman, Mauro W., Bu, Xianwei, Chen, Liang, McCaskill, Reva M., Zueger, Patrick, McDearmon-Blondell, Erin L., Pangan, Aileen L., Tillett, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217417/
https://www.ncbi.nlm.nih.gov/pubmed/33913086
http://dx.doi.org/10.1007/s40744-021-00305-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217417/
https://www.ncbi.nlm.nih.gov/pubmed/33913086
http://dx.doi.org/10.1007/s40744-021-00305-z

Ejemplares similares